ERBB2 and breast cancer: In solid tumor human breast cancer (BC) xenograft mouse models, the infusion of HER2/neu IgE-sensitized human MCs co-localized to BC cells, decreased the tumor burden and prolonged the overall survival without indications of toxicity [7].